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Abstract
Background: The aim of the study was to determine the maximal tolerated dose (MTD) of gemcitabine every two
weeks concurrent to radiotherapy, administered during an aggressive program of sequential and simultaneous
radiochemotherapy for locally advanced, unresectable non-small cell lung cancer (NSCLC) and to evaluate the efficacy
of this regime in a phase II study.
Methods: 33 patients with histologically confirmed NSCLC were enrolled in a combined radiochemotherapy protocol.
29 patients were assessable for evaluation of toxicity and tumor response. Treatment included two cycles of induction
chemotherapy with gemcitabine (1200 mg/m2) and vinorelbine (30 mg/m2) at day 1, 8 and 22, 29 followed by concurrent
radiotherapy (2.0 Gy/d; total dose 66.0 Gy) and chemotherapy with gemcitabine every two weeks at day 43, 57 and 71.
Radiotherapy planning included [18F] fluorodeoxyglucose positron emission tomography (FDG PET) based target volume
definition. 10 patients were included in the phase I study with an initial gemcitabine dose of 300 mg/m2. The dose of
gemcitabine was increased in steps of 100 mg/m2 until the MTD was realized.
Results: MTD was defined for the patient group receiving gemcitabine 500 mg/m2 due to grade 2 (next to grade 3)
esophagitis in all patients resulting in a mean body weight loss of 5 kg (SD = 1.4 kg), representing 8% of the initial weight.
These patients showed persisting dysphagia 3 to 4 weeks after completing radiotherapy. In accordance with expected
complications as esophagitis, dysphagia and odynophagia, we defined the MTD at this dose level, although no dose limiting
toxicity (DLT) grade 3 was reached.
In the phase I/II median follow-up was 15.7 months (4.1 to 42.6 months). The overall response rate after completion of
therapy was 64%. The median overall survival was 19.9 (95% CI: [10.1; 29.7]) months for all eligible patients. The median
disease-free survival for all patients was 8.7 (95% CI: [2.7; 14.6]) months.
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500 mg/m2 every two weeks in three cycles during a maximum of 7 weeks of thoracic radiotherapy for the phase II study.
This regimen represents an effective and tolerable therapy in the treatment of NSCLC.
Background
In recent years, a number of new, non-platinum agents
have demonstrated significant activity in advanced non-
small cell lung cancer (NSCLC). These substances include
taxanes, vinorelbine and gemcitabine [11]. The novel
agents generally have a toxicity profile superior to that of
platinum. This fact is highly important in a setting, in
which overall quality of life is a major consideration,
along with the control of lung cancer symptoms. Combi-
nations of these new drugs in doublets have yielded
results which are at least comparable with those achieva-
ble with cisplatin-containing regimens in stage IV of
NSCLC. The combination of gemcitabine and vinorelbine
proved to be particularly feasible; myelosuppression was
the most frequent toxicity. Most phase II trials reported
response rates of 20–40% and median survival duration
of 7–11 months [3,14,15,17].
For locally advanced NSCLC, new treatment approaches
utilise both radiotherapy and chemotherapy. Recent data
suggest a survival benefit from concomitant radiochemo-
therapy [1,4,7,16,20], but associated with high percent-
ages of therapy induced side effects, including
pneumonitis and esophagitis. The intensity of these toxic-
ities mainly depends on irradiated organ volume.
We conducted a phase I/II study combining gemcitabine
with concurrent thoracic radiotherapy in the treatment of
patients with locally advanced, unresectable NSCLC. To
minimize distant failure and to reduce irradiated volume,
we induced all patients with a regimen that consisted of
two 21-day cycles of vinorelbine and gemcitabine fol-
lowed by [18F] fluorodeoxyglucose positron emission
tomography (FDG PET) based evaluation of tumor
response and target volume definition.
In order to determine the maximal tolerated dose (MTD)
of gemcitabine every two weeks to a concurrent radiother-
apy administered during an aggressive program of
sequential and simultaneous radio-/chemotherapy an
upstream phase I study was initiated.
Methods
The Medical Ethics Committee of the University of
Aachen approved the phase I/II study. All patients gave
written informed consent before they were enrolled in the
study. Patient recruitment started in March 2003 and
ended in December 2005.
Patients
Patients with pathologically confirmed NSCLC and clini-
cally evaluated unresectable stage IIIa/b disease were eligi-
ble. Patients with a Karnofsky performance status of 80 to
100; age >18 years and forced expiratory volume in 1 sec-
ond ≥1.2 l were enrolled. Initial laboratory tests included
serum creatinine level ≤1.5 mg/dl; granulocyte count
≥2000/ml; platelet count ≥100000/ml; serum bilirubin
level ≤1.5 × the normal value; serum glutamic-oxaloacetic
transaminase level ≤2.5 × the normal value; and alkaline
phosphatase level ≤5 × the normal value. Exclusion crite-
ria were as follows: malignant pleural effusion and/or
pericardial effusion; recurrent disease after previous treat-
ment; history of another malignancy; history of anticancer
chemotherapy or RT; recent history of myocardial infarc-
tion, angina pectoris, congestive heart failure, or uncon-
trolled arrhythmia within 6 months of diagnosis;
pregnancy and missing written informed consent.
Chemotherapy
The induction chemotherapy consisted of 2 cycles gemcit-
abine (1200 mg/m2) and vinorelbine (30 mg/m2) given
on day 1, 8 (1.cycle) and on day 22, 29 (2.cycle). Gemcit-
abine was administered first as a 30-min i.v. infusion, fol-
lowed by vinorelbine given as a 5-min i.v. infusion.
In the phase I gemcitabine dose ranged between 300 and
500 mg/m2 in 100 mg/m2 increments. MTD was identified
for the patient group receiving gemcitabine 500 mg/m2
because of therapy induced esophagitis
Radiotherapy
The initial irradiated volume included the primary tumor,
the ipsilateral hilar lymph node regions and the mediasti-
nal lymph node regions with tumor invasion detected by
[18F] fluorodeoxyglucose positron emission tomography
(FDG PET). The location of lymph node regions within
the mediastinum has been described according to the
American Thoracic Society's definition (ATS map) [27].
Comparably to De Ruysscher et al, gross tumor volume
(GTV) included the postchemotherapy volume of the pri-
mary tumor, whereas for the lymph nodes only the pre-
treatment extension was taken into account [6]. The boost
target volume included the primary tumor and any gross
adenopathy detected by post chemotherapy FDG PET. To
ensure accurate and reproducible positioning setups, PET
and planning CT scans were performed using an immobi-
lization device. For the first patients target volumes were
delineated on planning computed tomography (CT)Page 2 of 10
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ratory gated CT scans as well as rigid co-registration of PET
and CT using a normalised mutual information algorithm
(Hermes®; Nuclear Diagnostics, Stockholm, Sweden).
Optimizing PET and CT fusion, CT scans in exspiration
were used. Radiotherapy was administrated with 10- or
15-MV photons. Radiation was delivered in 2-Gy fractions
daily for 5 days per week to a total dose of 50 Gy for the
initial volume. The boost target volume, received addi-
tional 16 Gy in the same dose fractionation. Isodose
curves and dose-volume histograms (DVHs) were calcu-
lated for the lungs, the esophagus, the heart and the spinal
cord. The maximum dose to any level of the spinal cord
did not exceed 45 Gy.
Dose modification
Dose modification of the gemcitabine and vinorelbine
application (induction chemotherapy) was specified for
myelosuppression and hepatic dysfunction, including a
therapy delay of 1 week. No dose reductions were allowed
in phase I of the study.
Assessment of response and toxicity
Toxicity was assessed using the CTC scale modified by
AIO/ARO/ADT. MTD was defined as the highest safely tol-
erated dose with toxicity levels that did not exceed any of
the following DLTs at one dose level: grade III hemato-
logic toxicities (≤ 2 of 6 patients); grade III cardiac or pul-
monary toxicity (≤ 2 of 6 patients); grade III esophagitis (≤
2 of 6 patients) and other unexpected, relevant grade III
toxicities (≤ 2 of 6 patients). The initial dose was given to
the first three patients. If none of these patients experi-
enced a DLT, then dose escalation proceeded to the next
level. If one of the first three patients experienced a DLT,
enrolment was continued until six patients were enrolled,
or a third DLT occurred. If the number of DLTs was ≤ 2,
dose escalation continued, otherwise dose escalation was
stopped.
Staging was done in accordance with the International
Staging System [18]. Pretreatment evaluation included
patient history, physical examination, routine laboratory
studies, computed tomography scans of the thorax, and
abdomen. Bone scans and FDG-PET were required ini-
tially. Pulmonary function was evaluated before induc-
tion therapy, 2 weeks after completion of the
chemotherapy and 6 weeks after the chemoradiotherapy
phase. Patients were monitored in weekly intervals for
adverse events by taking history, physical examination,
laboratory studies, and toxicity assessment during the
induction and consolidation treatment. Acute toxicity was
scored from the start to 3 months after the end of radio-
therapy. Late toxicity was scored more than 3 months after
the end of radiotherapy.
Restaging was performed 10 to 14 days after completion
of induction chemotherapy and 6 weeks after completion
of consolidation radiochemotherapy. Follow-up evalua-
tion consisted of medical history and physical examina-
tion with examinations of blood pressure and heart rate
followed by electrocardiogram and heart ultrasound in
the case of hypertension or irregular heart beat. In addi-
tion imaging studies including CT scans of the thorax and
abdomen as well as FDG-PET (for the first two follow-up
evaluations) or every 3 months for 18 months and every
6 months thereafter were performed. Tumor response was
evaluated by CT data according to response evaluation cri-
teria in solid tumors (RECIST). In the case of CT based
residual tumor without pathologic FDG uptake, complete
remission was defined.
Statistical methods
Categorical data were summarized by absolute and/or rel-
ative frequencies. Furthermore, 95% confidence intervals
for therapy response rates were computed according to the
method of Pearson and Clopper [5].
Patient follow-up times were condensed by median, min-
imum and maximum value, whereas the arithmetric mean
and the corresponding standard deviation (SD) were used
for data of all other continuous variables.
Observed values of various lung function parameters six
weeks respectively six months after therapy were com-
pared to corresponding baseline values using paired t-tests
on a global significance level of α = 0.05. The Bonferroni
method was used for multiple testing adjustment of the p-
values obtained from the 18 paired t-tests conducted;
adjusted p-values of p ≤ 0.05 can be interpreted as statisti-
cally significant test results.
Overall as well as disease-free survival times of the
patients were investigated by Kaplan-Meier survival anal-
ysis. Moreover, median overall as well as disease-free sur-
vival times and corresponding 95% confidence intervals
were calculated.
All confidence intervals computed were interpreted in a
solely descriptive manner. All statistical analyses were per-
formed using the SPSS® statistical analysis software pack-
age, version 12.0.
Results
Patients
A total of 33 patients were enrolled in this study from
March 2003 to December 2005: Ten patients onto the
phase I component and additional 23 patients onto the
phase II study. 29 patients were assessable for evaluation
of toxicity and response. One patient refused the second
cycle of chemotherapy after signing consent. ThreePage 3 of 10
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deterioration and death: acute myocardial infarction (1),
lung embolism (1) and histologically proven atypical
pneumonia caused by cytomegalovirus without leucope-
nia or neutropenia during the treatment (1). Patient char-
acteristics are listed in Table 1.
Radiotherapy
The heart was irradiated with a mean dose of 11.05 Gy
(SD = 7.01 Gy). The mean applied total lung dose was
12.31 Gy (SD = 2.64 Gy) based on a mean ipsilateral lung
dose of 19.85 Gy (SD = 4.03 Gy) and a mean contralateral
lung dose of 6.52 Gy (SD = 3.34 Gy). The mean ratio
between contralateral to ipsilateral lung volume was 1.22
with a mean ipsilateral lung volume of 1918.4 cm3 (SD =
679.4 cm3), and a mean contralateral lung volume of
2332.1 cm3 (SD = 556.3 cm3). The esophagus (mean vol-
ume = 37.8 cm3, SD = 10.6 cm3) was irradiated with a
mean dose of 29.0 Gy (SD = 6.4 Gy). The mean initial
planning target volume was 735.0 cm3 (SD = 266.7 cm3);
the mean boost volume was 399.7 cm3 (SD = 239.2 cm3).
Different dosimetric parameters for lung exposure are
listed in Table 2.
Toxicity
Toxicity caused by induction chemotherapy was predicta-
ble and acceptable. Only nonfebrile leucocytopenia and
clinically insignificant anaemia were observed. Four
patients (14%) of the phase II required treatment delays
during sequential chemotherapy caused by poststenotic
pneumonia without leucocytopenia or neutropenia.
Because of treatment delay and the necessity of effective
local tumor treatment, in three of these patients concur-
rent radiochemotherapy was started after only 3 applica-
tions of gemcitabine and vinorelbine. One patient
showed cardial symptoms including tachycardia and tho-
racic pain after application of vinorelbine. Consequently
gemcitabine was not infused. Representing a unique effect
without pathologic findings in cardial examination, the
subsequent chemotherapy could be applied routinely.
Analysing late cardiac side effects, one patient showed
minimal pericardial effusion being treated with a diuretic.
No significant change in blood pressure or irregular heart
beat was diagnosed.
Significant esophageal and pulmonary toxicities were
encountered as a result of concurrent treatment. In the
third group (500 mg/m2) of the phase I, grade 2 esophag-
itis was encountered in all four patients. In contrast to the
second group receiving 400 mg/m2, where two patients
showed grade 2 esophagitis including moderate dys-
phagia, all 4 patients in the third group showed severe
dysphagia making intensified local treatment necessary.
They showed a mean body weight loss of 5 kg (SD = 1.4
kg) representing 8% of the initial weight. Furthermore
these patients showed persisting dysphagia 3 to 4 weeks
after completing radiotherapy. Three months after finish-
ing therapy none of the four patients described persisting
dysphagia.
Because of the described severe increase in esophagitis in
the third group and the expected complications such as
severe dysphagia and odynophagia, ulceration or occlu-
sion, we did not realize the next step of dose escalation.
We defined the MTD at a dose level of 500 mg/m2 every
two weeks, although no dose-limiting toxicity grade 3
according to CTC criteria was reached [9].
In the phase II study, 7 patients showed grade 3 esophag-
itis (30%), two patients required treatment delays. One of
these patients developed hemoragic esophagitis resulting
in a 10 day treatment delay whereas in the other case treat-
ment could be continued after a 6 day break. No dose-lim-
iting esophagitis was observed. None of the patients
required gastrostomy tubes or esophageal dilation. Pre-
maturely termination of radiochemotherapy after 58.0 Gy
was necessary in two patients of the phase II study. One
patient showed tumor progression during radiochemo-
therapy including local progression as well as pulmonary
metastases. The other patient developed dose-limiting
acute pulmonary toxicity (grade 3), presented with fever,
dyspnea, and infiltrates.
Four patients in the phase II developed reversible grade 3
pulmonary toxicity one to six weeks after finishing radio-
therapy with local advanced pulmonary infiltrates in CT
scans. According to clinical pulmonary symptoms, all
patients were treated with steroids and antibiotic i.v. as
well as oxygen, reaching adequate stabilization of their
symptoms within one week. Toxicities during induction
chemotherapy and radiochemotherapy are summarized
in Table 3.
One patient of the phase II developed cough and dyspnea
three weeks after radiochemotherapy. Radiographic pul-
monary infiltrates according to an atypical pneumonia
were diagnosed. These infiltrates were distributed sym-
metrically in both lobes of the lung. There was no accord-
ance to the irradiation fields, making radiation induced
pneumonia improbable. The patient died of progressive
respiratory failure. Refusing post-mortem examination it
was impossible to clarify the exact causes of pneumonia.
In order to detect therapy induced side effects, lung func-
tion was tested in 25 patients six weeks and in 20 patients
six months after radiochemotherapy, excluding patients
with progressive disease in the lung. The development in
lung function parameters and the mean differences six
weeks and six months after finishing radiochemotherapyPage 4 of 10
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tion parameters were found.
Tumor response
Median overall follow-up was 15.7 months (4.1 to 42.6
months), the mean observation time in survivors was 21.7
months (5.9 to 42.6 months). Tumor regression after
induction chemotherapy could be diagnosed in 19 assess-
able patients. None of the patients developed progressive
disease (distant metastases or local tumor progression).
After radiochemotherapy 11 patients reached a complete
remission. The local overall response rate (including
response of primary tumor and metastatic lymph nodes)
after completion of therapy was 83% (95% CI: [64%;
94%]). Analysing local tumor response, 13 patients
showed a local partial remission, 2 patients a local stable
disease and 3 patients a local progressive disease. 8 of
these 18 patients without complete remission still had
metastases in PET at the first follow up resulting in an
overall response rate of 62% (95% CI: [42%; 79%]). The
median overall survival was 19.9 (95% CI: [10.1; 29.7])
months for all eligible patients (Figure 1). The median
disease-free survival for all patients was 8.7 (95% CI: [2.7;
14.6]) months (Figure 2). Table 5 shows the response
rates six to twelve weeks after radiochemotherapy. In
Table 6 the sites of initial relapse are listed.
Discrepancy between disease-free survival and overall sur-
vival was caused by three patients. Five months after
reaching complete remission one patient developed an
increase of bilateral hilar lymph nodes in CT as well as an
increase of mean SUV up to 6.4. Second line chemother-
apy (carboplatin/paclitaxel) was started without histolog-
ical verification of malignity. 12 months after second line
Table 1: Characteristics of population
Dose Level
300 mg/m2 400 mg/m2 500 mg/m2
No. of patients 3 3 23
Age (years)
Mean 68 50 58
Range 63–75 42–62 40–75
Sex
Male 3 1 17
Female 0 2 6
Karnofsky Performance Status
100% 2 1 9
90% 0 1 7
80% 1 1 7
Clinical stage
cT2cN3 0 0 2
cT3cN2 2 0 1
cT3cN3 0 0 6
cT4 cN0 0 0 6
cT4 cN2 0 2 5
cT4 cN3 1 1 3
Histology
Adenocarcinoma 0 2 6
Squamous Carcinoma 1 1 15
Adenosquamous Carcinoma 1 0 1
Large-Cell Carcinoma 1 0 1
Table 2: Descriptive summary of dosimetric parameters for lung exposure
Total Lung Ipsilat. Lung Contralat. Lung
Mean SD Mean SD Mean SD
Mean Lung Dose 12.31 2.64 19.85 4.03 6.52 3.34
V20 26.77 7.61 44.64 9.87 13.55 8.85
V30 20.26 5.47 36.00 6.51 8.55 6.66
V40 15.93 5.01 30.00 5.50 5.59 4.99Page 5 of 10
(page number not for citation purposes)
BMC Cancer 2007, 7:112 http://www.biomedcentral.com/1471-2407/7/112treatment, there was still a stable SUV of 2.7 at the hilar
lymph nodes with stable extension in CT. One patient
showed stable partial remission in CT and stable local
mean SUV of 3.1 to 3.8 for a time interval of 13 months
after radiochemotherapy. In another patient single metas-
tasis of the right suprarenal gland was detected. Receiving
stereotactic irradiation with 5 × 8.0 Gy (80% isodose) this
patient reached complete remission for the last 23
months.
Discussion
The use of induction chemotherapy has been developed
through a series of clinical trials since the mid-1980s. The
Cancer and Leukemia Group B (CALGB) 8433 trial dem-
onstrated significant improvements in the combined
modality therapy group, with a longer median survival
time (13.7 months vs. 9.6 months; p = 0.012) and higher
5-year survival rate of 17% versus 6% [7].
Several phase III trials compared concurrent radiochemo-
therapy with radiotherapy alone. The first of these trials
was performed by the European Organization for
Research and Treatment of Cancer (EORTC). In that trial,
331 patients were randomized to three treatment pro-
grams [21]. The 3-year survival rate was significantly
greater with the daily application of cisplatin (arm 3) than
with the thoracic radiotherapy alone (arm1) (16% vs. 2%;
p = 0.009). The survival benefit of weekly cisplatin (arm
2) was intermediate and not statistically different from
both groups. The time to local recurrence was significantly
longer in the cisplatin groups (p = 0.015), especially the
group with cisplatin daily (p = 0.003).
The consequence was the conduction of several trials
comparing systemic chemotherapy plus concurrent radio-
therapy with several cycles of systemic chemotherapy fol-
lowed by radiotherapy (sequential approach). In the NPC
95-01 study patients were randomly assigned to receive
sequential or concurrent therapy [8]. In the sequential
arm, three cycles of chemotherapy were administered first,
consisting of cisplatin and vinorelbine, followed by tho-
racic RT at a dose of 66 Gy in 33 fractions (2 Gy per frac-
tion, 5 fractions per week) at day 78. In the concurrent
arm, the same radiotherapy was started on day 1 with two
concurrent cycles of cisplatin and etoposide (days 1 to 5
and days 29 to 33). The patients received two cycles con-
solidation therapy with cisplatin and vinorelbine after-
wards. The median survival was 14.5 (95% CI: [8.3; 27.4])
months in the sequential arm and 16.3 (95% CI: [5.8;
34.8]) months in the concurrent treatment. Nevertheless
this difference was not significant. Esophageal toxicity was
significantly more frequent in the concurrent arm than in
the sequential arm (32% vs. 3%). Analysing treatment
protocol 88% of the patients in the concurrent arm but
Table 4: Descriptive summary of baseline values of various lung function parameters as well as of differences in those variables 
between baseline values and values obtained 6 weeks respectively 6 months after radiochemotherapy (RT/CHT.); corresponding p-
values were calculated by conducting paired t-tests assessing whether those differences deviate statistically significant from zero.
Baseline 6 Weeks after RT/CHT vs Baseline 6 Months after RT/CHT vs Baseline
Mean SD Mean Diff. SD p-value Mean Diff. SD p-value
FVC (L) 3.25 0.83 -0.01 0.55 1.00 -0.18 0.45 1.00
FEV1 (L) 2.16 0.70 -0.02 0.32 1.00 -0.14 0.28 0.72
FEV1/VC (%) 63.62 15.38 2.86 17.06 1.00 2.91 14.16 1.00
RV (L) 3.01 0.82 -0.30 0.47 0.16 -0.11 0.71 1.00
TLC (L) 6.25 1.22 -0.33 0.72 0.54 -0.29 0.71 1.00
RV/TLC (%) 47.91 7.76 -2.35 5.85 1.00 -0.42 7.19 1.00
KCO (ml/(min*mmHg*L)) 5.74 2.26 -0.34 1.49 1.00 0.08 2.32 1.00
Pao2 (mmHg) 62.89 6.40 2.61 6.24 1.00 0.27 6.53 1.00
Paco2 (mmHg) 39.12 2.71 -2.01 3.97 0.54 -1.47 3.70 1.00
Table 3: Events of toxicity during chemo- and radiochemotherapy (* = phase I study)
Esophageal Pulmonary Hematologic
G1 G2 G3 G1 G2 G3 G1 G2 G3
Gemcitabine (mg/m2) No. 3 19 7 18 6 5 12 9 1
300* 3 1 2 0 1 2 0 1 1 0
400* 3 1 2 0 1 2 0 1 2 0
500* 4 0 4 0 4 0 0 0 1 0
500 19 1 11 7 12 2 5 10 5 1Page 6 of 10
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dose higher than 60 Gy. This imbalance in radiotherapy
was also described by Zatloukal et al, comparing concur-
rent versus sequential radiochemotherapy with cisplatin
and vinorelbine in a randomised trial [28].
In our study we supplied gemcitabine and vinorelbine as
dose intense induction chemotherapy in a short time
interval of two weeks, in order to kill malignant cells in
existing micro-metastases and to reduce the planning tar-
get volume (PTV). The latter could be realized in 19 of 29
patients receiving a tumor regression after induction
chemotherapy. Recent studies in patients with solid
tumors have shown it's value as a radiotherapy enhancer,
even at doses substantially below those required for cyto-
toxic effects [23-26]. Therefore we used gemcitabine as a
radiotherapy enhancer in a dose intense treatment to
improve local tumor control. On the basis of a possible
accumulation of side effects after intensified induction
chemotherapy, a dose-finding study was carried out to
minimize radiation-induced complications. Furthermore,
gemcitabine was administered only once every two weeks,
concurrent to irradiation to avoid dose reduction in radi-
otherapy. In the phase II, only two patients needed pre-
mature termination of radiochemotherapy after 58.0 Gy.
One patient showed tumor progression during radioche-
motherapy, the other patient developed dose-limiting
acute pulmonary toxicity (grade 3). Because of reduced
lung function in combination with high lung exposure in
six patients (21%) the applied total dose was reduced to
60.0 Gy.
In the phase I, dose-limiting toxicity (DLT) was identified
for the patient group receiving gemcitabine 500 mg/m2,
due to grade 2 esophagitis (next to grade 3) in all patients.
In accordance with expected complications, such as
esophagitis, dysphagia and odynophagia, we defined the
MTD at this dose level although no DLT grade 3 occurred.
Table 5: Local tumor response and overall tumor response six to twelve weeks after treatment
Local Response
After Radiochemotherapy CR PR SD PD
Gemcitabine (mg/m2) No. of Patients
300 3 1 2 - -
400 3 1 1 - 1
500 23 9 10 2 2
Overall Response
After Radiochemotherapy CR PR SD PD
300 3 1 1 - 1
400 3 1 0 - 2
500 23 9 6 2 6
CR = complete remission, PR = partial remission, SD = stable disease, PD = progressive disease
Table 6: Sites of initial relapse
Site of tumor progression Cohort
300 mg/m2 400 mg/m2 500 mg/m2
No. of Patients 3 3 23
Locoregional – Infield 2 1 8
Locoregional – Outfield 2 - -
Locoregional – Infield and Distant 1 - 3
Locoregional – Outfield and 
Distant
- - -
Distant only - 1 4
Brain - - 3
Death without Progression - - 1Page 7 of 10
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clinical symptoms because of different scores and interin-
stitutional ambiguity in the scoring of esophagitis cases
for lung cancer patients, as well as differences in policy to
prescribe analgetics or i.v. fluids and hyperalimentation
(indicative for grade 3–4 esophagitis) [9]. According to
CTC criteria modified by AIO/ARO/ADT, grade 3 toxicity
was defined as very painful dysphagia, oedema or ulcera-
tion with necessity of pure/liquid diet or analgetics. In
contrast to the phase I study where we avoided systemic
analgetics, we used it in the phase II study in combination
with supportive hyperalimentation(per definition grade 3
toxicity) resulting in grade 3 esophagitis in 37% of the
patients. Consequently only two of these patients
required treatment delays with one patient developing
hemoragic esophagitis. No dose-limiting esophagitis was
developed.
In the phase II study five patients developed grade 3 pul-
monary toxicities. Based on CT scans and lung function
testing in four of these patients, advanced pulmonary
emphysema based on chronic obstructive pulmonary dis-
ease was diagnosed, increasing the risk of radiation
induced pneumonia [19]. All patients were treated with
steroids and antibiotics i.v. as well as oxygen, reaching
adequate stabilization and relief of their symptoms within
one to two weeks. Analysing the different lung parame-
ters, we found only a slight decrease of FEV1 of at mean
0.14 l.
In a prospective study, Kalff et al found that FDG PET
scanning changed or influenced management decisions in
67% of patients with NSCLC [13]. Patients were fre-
quently spared unnecessary treatment, and management
was more appropriately targeted. According to radiother-
apy, PET influenced the intent, modality, or delivery of
treatment in 36 (64%) of 56 patients, as compared to a
prospectively recorded pre-PET plan. In our study, addi-
tional organ metastases were diagnosed by the use of
FDG-PET in four patients that had not been detected in CT
scans of the thorax and abdomen.
Analysing FDG-PET in problematic mediastinal lymph
node staging, a sensitivity of 80% and specificity of 88%
can be expected [12]. In addition, a good correlation
between histological regression grades after radiochemo-
therapy and metabolic remission as detected by PET could
be shown [22]. If chemotherapy is effective as a systemic
adjuvant therapy, it should also enable to control occult
microscopic nodal disease, obviating the need of elective
nodal irradiation [2]. Therefore we used the initial FDG
PET for definition of nodal irradiation, including the pri-
mary involved lymph node regions or the regions with
high risk of tumor invasion. After 50.0 Gy, only the gross
tumor volume, as identified after induction chemother-
apy in the second FDG PET, was irradiated resulting in a
target volume reduction of 335.3 cm3 (SD = 239.2 cm3).
In order to emphasize the effectiveness of PET based target
volume definition, local tumor response was evaluated.
Only in two patients (7%) locoregional outfield relapses
were observed.
In the future, biological images which detect probable
resistance to therapy, such as hypoxic tumor regions, i.e.
through the use of [18F] fluoromisonidazole positron
emission tomography (FMISO-PET), may provide infor-
mation for defining a biological target volume (BTV) to
improve local control and simultaneously reduce the
exposure of organs at risk [10].
Conclusion
Gemcitabine and vinorelbine as induction chemotherapy,
followed by gemcitabine concurrent with thoracic radio-
therapy every two weeks is feasible. Esophagitis was found
to be the DLT of gemcitabine with thoracic irradiation.
Hematological side effects were moderate. We recom-
mend a gemcitabine dose of 500 mg/m2 every two weeks,
when administered with thoracic radiotherapy for 6 to 7
weeks. Although there was increase in esophageal and
pulmonal toxicity in phase II, this treatment modality is
well tolerated. Because of favourable survival and accept-
able toxicity profile, we consider this radiochemotherapy
regime combined with PET based target volume defini-
tion as a warrant for further evaluation.
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